ORYZON Reveals 2024 Shareholder Meeting Voting Results

Oryzon Genomics, S.A., a clinical-stage biopharmaceutical company specializing in epigenetics, recently held its Annual General Meeting of Shareholders in Madrid. At the meeting, 27,110,751 issued and outstanding common shares, representing 42.6867% of the capital stock, were represented either in person or by proxy.

Several key resolutions proposed by the Board of Directors were approved with favorable votes ranging from 96% to 79%. These resolutions included the approval of the annual report and financial statements for the year 2023, the appropriation of loss, and the discharge of the members of the Board of Directors. Additionally, shareholders approved the election of a new audit firm, KPMG, for the years 2024-2026, as well as customary delegations to formalize and notarize the resolutions.

Significantly, an additional resolution to increase capital for up to 100 million euros was also approved. This will be achieved through cash contributions and will exclude pre-emptive subscription rights. The Board of Directors has been delegated the power to set the date, the issue price, and other conditions of the issuance in accordance with the provisions of Article 505 of the Spanish Companies Act.

Oryzon Genomics, founded in 2000 in Barcelona, Spain, is recognized as a leader in the field of epigenetics and focuses on personalized medicine for central nervous system (CNS) disorders and oncology. The company boasts a skilled team of professionals from the pharmaceutical industry, with offices located in Barcelona, Boston, and San Diego.

In terms of its clinical portfolio, Oryzon has advanced to Phase II clinical trials with its two LSD1 inhibitors, vafidemstat for CNS disorders and iadademstat for oncology. Additionally, the company has other pipeline assets targeting epigenetic mechanisms, such as HDAC-6. ORY-4001 has been nominated as a clinical candidate for treating certain neurological disorders, including Charcot-Marie-Tooth (CMT) disease and amyotrophic lateral sclerosis (ALS).

Oryzon Genomics also maintains a robust platform for biomarker identification and target validation for various malignant and neurological diseases. This platform is crucial for the development of personalized medical therapies that address unmet clinical needs.

Oryzon continues to advance its mission of addressing significant unmet medical needs through its innovative work in epigenetics, leveraging its extensive clinical portfolio and research capabilities to push the boundaries of personalized medicine in both CNS disorders and oncology.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!